<p>有時，跳入生物科技等行業的最佳方式是跟隨熱門交易。儘管這可能違反了避免炒作週期和害怕錯過的常見建議，但查看哪些生物科技股票正在經歷最高的 24 小時交易量可以快速瞭解是哪些催化劑正在推動投資者進入該行業。</p>
<p>這是因為生物科技行業在估計患者人口規模來預測未來藥品產品或治療需求方面具有獨特性。例如，旨在治療或預防病毒的藥物具有無限的收入潛力，而治療遺傳性疾病的藥物受到世界上患有該疾病的人數限制。</p>
<p>因此，投資者可以利用這些廣泛的數字估計來評估生物科技股票的整體潛力，進行研究和組合選擇。</p>
<h2>輝瑞（PFE）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：photobyphm / Shutterstock.com</p>
<p>在過去 24 小時內交易了 39,753,100 股的 <strong>輝瑞</strong>（紐約證券交易所：<strong>PFE</strong>）似乎重新成為焦點，因為它目前是交易量最大的生物科技股票。投資者的興奮可能是因為輝瑞第二季度的收入大幅超出先前預期，公司提高了全年展望。即使在這個藥品製造商正努力削減運營成本的時候，這一點也是如此，因為人們擔心其新冠疫情產品將不再在市場上具備競爭力。</p>
<p>目前，公司的許多財務增長主要來自收購的藥物和最近推出的治療方案，成功抵消了新冠疫情產品需求下降。這突顯了投資於像輝瑞這樣的大型生物科技公司的現實，即公司既有資源又有規模，可以持續在市場上創造機會。因此，PFE 股票是當今交易中最熱門的生物科技股票之一。</p>
<h2>默克（MRK）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Shutterstock</p>
<p>另一方面，<strong>默克</strong>（紐約證券交易所：<strong>MRK</strong>）在第二季度財報公佈後，股價下跌，儘管財務指標相對穩定。在過去 24 小時內交易了 14,117,400 股，默克的投資者要麼是在恐慌中拋售，要麼是在買入低點。但股票的長期動態可能正在發生變化。</p>
<p>這是因為公司的一款關鍵突破性人乳頭瘤病毒（HPV）疫苗在其關鍵的中國市場需求開始下滑。這種名為 Gardasil 的藥物是默克過去幾年的主要收入來源，但如果公司在海外擴大采用困難，銷售可能會停滯。</p>
<p>此外，默克面臨着其暢銷癌症藥物 Keytruda 之一的專利在 2028 年到期。儘管這還有幾年的時間，但這意味着 MRK 一直享有的 Keytruda 患者羣體無競爭環境將消失，最終影響價格和銷售。雖然這對 MRK 投資者來説是一種損失，但更便宜的癌症藥物對患者來説總是一種勝利。</p>
<h2>治療藥物（TEVA）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>來源：Jonathan Weiss / Shutterstock</p>
<p>在過去 24 小時內交易了 15,705,600 股的 <strong>治療藥物</strong>（紐約證券交易所：<strong>TEVA</strong>）可能意味着公司在製藥領域的綜合方法取得了成功。該公司悄悄積累了全球最大的 3500 種不同產品的仿製藥組合。它現在為全球 58 個國家的患者提供服務，全球近 2 億人每天服用治療藥物。</p>
<p>因此，治療藥物最大的資產是時間，因為隨着品牌藥物隨着時間失去專利保護，公司將繼續獲得新的仿製藥配方。對於投資者來説，這意味着今天在治療藥物中的早期位置可能會在未來轉化為一個利潤豐厚的持有，當許多已經最有效的配方完全成為仿製藥並對廣大人羣可負擔時。</p>
<p>考慮到這種潛在發展軌跡和其成功的第二季度財務增長，TEVA 股票可能會繼續是市場上最受歡迎的生物科技股票之一。</p>
<p>_在發佈日期，Viktor Zarev 在本文提到的證券中沒有（直接或間接）任何頭寸。本文中表達的觀點屬於作者，遵守 InvestorPlace.com 的發佈指南。</p>
<p>_在發佈日期，負責編輯在本文提到的證券中沒有（直接或間接）任何頭寸。</p>
<p>Viktor Zarev 是一位科學家、研究員和作家，專門通過對準確性和理解的奉獻來解釋技術股票的複雜世界。</p>
<p>生物科技、醫療保健</p>

輝瑞

默克

<p>目前最熱門的生物科技股票是輝瑞（PFE）、默克（MRK）和特瓦製藥（TEVA）。由於強勁的第二季度收入和積極的前景，輝瑞的股票交易量較高。默克的股票面臨着挑戰，因為其宮頸癌疫苗需求下降，且其癌症藥物即將面臨專利到期。特瓦製藥在其仿製藥產品組合方面取得成功，並預計在市場上保持受歡迎程度</p>

<p>Sometimes the best way to jump into an industry like biotech is to follow the popular trades. Though that may go against the common advice of avoiding hype cycles and the fear of missing out, seeing which biotech stocks are experiencing the highest 24-hour trading volumes can be a quick way to learn which catalysts are driving investors to the industry.</p>
<div class="lb-trans"><p>有時，跳入生物科技等行業的最佳方式是跟隨熱門交易。儘管這可能違反了避免炒作週期和害怕錯過的常見建議，但查看哪些生物科技股票正在經歷最高的 24 小時交易量可以快速瞭解是哪些催化劑正在推動投資者進入該行業。</p>
</div><p>That’s because the biotech industry is unique in its ability to forecast demand for a future drug product or treatment by estimating the size of a patient population. For example, drugs intended to treat or prevent viruses have limitless revenue potential while drugs that treat hereditary or genetic diseases are constrained in sales by the number of people in the world born with the disease.</p>
<div class="lb-trans"><p>這是因為生物科技行業在估計患者人口規模來預測未來藥品產品或治療需求方面具有獨特性。例如，旨在治療或預防病毒的藥物具有無限的收入潛力，而治療遺傳性疾病的藥物受到世界上患有該疾病的人數限制。</p>
</div><p>As such, investors can use these kinds of broad numerical estimates to gauge the overall potential of biotech stocks for research and portfolio selection.</p>
<div class="lb-trans"><p>因此，投資者可以利用這些廣泛的數字估計來評估生物科技股票的整體潛力，進行研究和組合選擇。</p>
</div><h2>Pfizer (PFE)</h2>
<div class="lb-trans"><h2>輝瑞（PFE）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: photobyphm / Shutterstock.com</p>
<div class="lb-trans"><p>來源：photobyphm / Shutterstock.com</p>
</div><p>With 39,753,100 shares trading in the last 24 hours, <strong>Pfizer</strong>(NYSE:<strong>PFE</strong>) seems to be back in the spotlight as it is currently the most traded biotech stock by volume. The investor excitement likely comes as a result of Pfizer’s second-quarter revenue handily exceeding previous expectations as the company raises its full-year outlook. This comes even at a time when the drugmaker is working to cut operational costs amid worries its Covid-19 products will no longer be relevant in the market.</p>
<div class="lb-trans"><p>在過去 24 小時內交易了 39,753,100 股的 <strong>輝瑞</strong>（紐約證券交易所：<strong>PFE</strong>）似乎重新成為焦點，因為它目前是交易量最大的生物科技股票。投資者的興奮可能是因為輝瑞第二季度的收入大幅超出先前預期，公司提高了全年展望。即使在這個藥品製造商正努力削減運營成本的時候，這一點也是如此，因為人們擔心其新冠疫情產品將不再在市場上具備競爭力。</p>
</div><p>Currently, much of the company’s financial growth stems from acquired drugs and more recently launched treatments which have successfully offset the dip in Covid-19 product demand. This highlights the reality of investing in a large biotech corporation like Pfizer, which is that the company has both the resources and the mass to consistently create its opportunities in the market. As a result, PFE stock is among the hottest biotech stocks trading today.</p>
<div class="lb-trans"><p>目前，公司的許多財務增長主要來自收購的藥物和最近推出的治療方案，成功抵消了新冠疫情產品需求下降。這突顯了投資於像輝瑞這樣的大型生物科技公司的現實，即公司既有資源又有規模，可以持續在市場上創造機會。因此，PFE 股票是當今交易中最熱門的生物科技股票之一。</p>
</div><h2>Merck (MRK)</h2>
<div class="lb-trans"><h2>默克（MRK）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Shutterstock</p>
<div class="lb-trans"><p>來源：Shutterstock</p>
</div><p>On the other side of the investing coin, <strong>Merck</strong>(NYSE:<strong>MRK</strong>) saw shares fall following its second-quarter earnings report, despite relatively steady financial metrics. With 14,117,400 shares moving in the last 24 hours, Merck investors are either selling in response to panic or buying the dip. But the long-term dynamics for the stock could be changing regardless.</p>
<div class="lb-trans"><p>另一方面，<strong>默克</strong>（紐約證券交易所：<strong>MRK</strong>）在第二季度財報公佈後，股價下跌，儘管財務指標相對穩定。在過去 24 小時內交易了 14,117,400 股，默克的投資者要麼是在恐慌中拋售，要麼是在買入低點。但股票的長期動態可能正在發生變化。</p>
</div><p>That’s because one of the company’s key breakthrough vaccines for human papillomavirus (HPV) has seen demand begin to slip in its critical Chinese market. The drug, known as Gardasil, has been one of Merck’s main revenue drivers over the last few years, but should the company struggle to expand its adoption abroad, sales will likely stagnate.</p>
<div class="lb-trans"><p>這是因為公司的一款關鍵突破性人乳頭瘤病毒（HPV）疫苗在其關鍵的中國市場需求開始下滑。這種名為 Gardasil 的藥物是默克過去幾年的主要收入來源，但如果公司在海外擴大采用困難，銷售可能會停滯。</p>
</div><p>Beyond this, Merck faces the patent expiration of one of its best-selling cancer drugs, Keytruda, in 2028. While that’s still a handful of years away, it means the competition-free environment MRK has enjoyed for Keytruda’s patient population will vanish, ultimately impacting price and sales. While it’s a loss for MRK investors, cheaper cancer drugs are always a win for patients.</p>
<div class="lb-trans"><p>此外，默克面臨着其暢銷癌症藥物 Keytruda 之一的專利在 2028 年到期。儘管這還有幾年的時間，但這意味着 MRK 一直享有的 Keytruda 患者羣體無競爭環境將消失，最終影響價格和銷售。雖然這對 MRK 投資者來説是一種損失，但更便宜的癌症藥物對患者來説總是一種勝利。</p>
</div><h2>Teva Pharmaceuticals (TEVA)</h2>
<div class="lb-trans"><h2>治療藥物（TEVA）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Jonathan Weiss / Shutterstock</p>
<div class="lb-trans"><p>來源：Jonathan Weiss / Shutterstock</p>
</div><p>Seeing 15,705,600 shares of <strong>Teva Pharmaceuticals</strong>(NYSE:<strong>TEVA</strong>) trade in the past 24 hours likely means the company’s generalist approach to the pharmaceutical sector is succeeding. The company has quietly amassed the world’s largest generic drug portfolio of 3,500 different products. It now serves patients in over 58 countries, with nearly 200 million people around the globe taking Teva medicine daily.</p>
<div class="lb-trans"><p>在過去 24 小時內交易了 15,705,600 股的 <strong>治療藥物</strong>（紐約證券交易所：<strong>TEVA</strong>）可能意味着公司在製藥領域的綜合方法取得了成功。該公司悄悄積累了全球最大的 3500 種不同產品的仿製藥組合。它現在為全球 58 個國家的患者提供服務，全球近 2 億人每天服用治療藥物。</p>
</div><p>Thus, Teva’s greatest asset is time, as the company will only continue to acquire new generic drug recipes as brand-name drugs lose their patent protection over time. For investors, this means an early position in Teva today could translate to a lucrative holding far into the future when many of the already most effective formulas are fully generic and affordable to vast population groups.</p>
<div class="lb-trans"><p>因此，治療藥物最大的資產是時間，因為隨着品牌藥物隨着時間失去專利保護，公司將繼續獲得新的仿製藥配方。對於投資者來説，這意味着今天在治療藥物中的早期位置可能會在未來轉化為一個利潤豐厚的持有，當許多已經最有效的配方完全成為仿製藥並對廣大人羣可負擔時。</p>
</div><p>With this potential trajectory and its successful second-quarter financial growth, TEVA stock will likely remain among the most popularly traded biotech stocks on the market.</p>
<div class="lb-trans"><p>考慮到這種潛在發展軌跡和其成功的第二季度財務增長，TEVA 股票可能會繼續是市場上最受歡迎的生物科技股票之一。</p>
</div><p><em>On the date of publication, Viktor Zarev did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p>_在發佈日期，Viktor Zarev 在本文提到的證券中沒有（直接或間接）任何頭寸。本文中表達的觀點屬於作者，遵守 InvestorPlace.com 的發佈指南。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p>_在發佈日期，負責編輯在本文提到的證券中沒有（直接或間接）任何頭寸。</p>
</div><p>Viktor Zarev is a scientist, researcher, and writer specializing in explaining the complex world of technology stocks through dedication to accuracy and understanding.</p>
<div class="lb-trans"><p>Viktor Zarev 是一位科學家、研究員和作家，專門通過對準確性和理解的奉獻來解釋技術股票的複雜世界。</p>
</div><p>Biotech, Healthcare</p>
<div class="lb-trans"><p>生物科技、醫療保健</p>
</div>

What Are the Hottest Biotech Stocks Right Now? 3 Top Picks.

- 達到生物科技行業的最佳途徑之一是關注熱門交易。儘管這可能違背避免炒作週期和錯失機會的常見建議，但查看哪些生物科技股票在過去 24 小時內交易量最高，可以快速瞭解推動投資者進入該行業的催化劑。
- 生物科技行業獨特之處在於通過估計患者人羣規模來預測未來藥品或治療的需求。例如，旨在治療或預防病毒的藥物具有無限的收入潛力，而治療遺傳疾病的藥物受到世界上患有該疾病的人數限制。
- 投資者可以利用這些廣泛的數字估計來評估生物科技股票的整體潛力，用於研究和組合選擇。

目前最熱門的生物科技股票有哪些？3 個頂級推薦